• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Atea Pharmaceuticals, Inc. - common stock (NQ:AVIR)

    3.445 +0.045 (+1.32%)
    Streaming Delayed Price Updated: 11:10 AM EST, Jan 20, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Atea Pharmaceuticals, Inc. - common stock

    < Previous 1 2 3 Next >
    News headline image
    Atea Pharmaceuticals to Highlight 2026 Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference
    From Atea Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Atea Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
    From Atea Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Atea Pharmaceuticals Completes Patient Enrollment in North American Phase 3 Trial Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
    From Atea Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Atea Pharmaceuticals to Present at the 8th Annual Evercore Healthcare Conference
    From Atea Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Atea Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
    From Atea Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Atea Pharmaceuticals to Host Third Quarter 2025 Financial Results and Business Update Conference Call on November 12, 2025
    From Atea Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Atea Pharmaceuticals Presents New Data Supporting the Fixed-Dose Combination of Bemnifosbuvir and Ruzasvir as a Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025
    Company Hosting Virtual KOL Panel Event Thursday, November 13th at 10:00 AM ET 
    From Atea Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Atea Pharmaceuticals to Host Virtual HCV KOL Panel Event on November 13, 2025
    From Atea Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Atea Pharmaceuticals to Present New Data Supporting Combination of Bemnifosbuvir and Ruzasvir as Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025
    From Atea Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Atea Pharmaceuticals to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
    From Atea Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Atea Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
    From Atea Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Atea Pharmaceuticals to Host Second Quarter 2025 Financial Results and Business Update Conference Call on August 7, 2025
    From Atea Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Atea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing of First Patient in C-FORWARD Outside North America
    From Atea Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
    From Atea Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Atea Pharmaceuticals Announces Full Results from Phase 2 Study of Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (HCV) Presented at EASL Congress 2025
    From Atea Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Atea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025
    From Atea Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Atea Pharmaceuticals to Present New Data Showcasing Potential Best-in-Class Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2025
    From Atea Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program
    Enters into Agreement with Bradley L. Radoff and Michael Torok 
    From Atea Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Atea Pharmaceuticals Announces Dosing of First Patient in C-BEYOND, Phase 3 Study Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
    From Atea Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Atea Pharmaceuticals Highlights Actions Underway to Enhance Shareholder Value
    From Atea Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors
    From On Behalf of The Radoff-JEC Group
    Via Business Wire
    News headline image
    Atea Pharmaceuticals Issues Statement Regarding Director Nominations
    No Shareholder Action is Required at this Time 
    From Atea Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Atea Pharmaceuticals Announces Presentation of Bemnifosbuvir Preclinical Data at the 38th International Conference on Antiviral Research (ICAR) 2025
    From Atea Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
    From Atea Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on March 6, 2025
    From Atea Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors
    From Atea Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Atea Pharmaceuticals to Highlight 2025 Strategic Priorities at the 43rd Annual J.P. Morgan Healthcare Conference
    From Atea Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Atea Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
    From Atea Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Atea Pharmaceuticals Retains Financial Advisor to Explore Strategic Partnerships
    From Atea Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Atea Pharmaceuticals Announces Positive Results from Phase 2 Study of Bemnifosbuvir and Ruzasvir Regimen for Treatment of Hepatitis C Virus (HCV)
    From Atea Pharmaceuticals, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.